IP Library Patent Application 14106533
Patent Application
App. No. 14/106,533

Methods for Treating Alzheimer's Disease

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/106,533
Abstract

Cognitive impairments in humans with Alzheimer's disease are treated by administering a composition that includes an amphetamine compound. Memory, attention and executive function can be improved following administration of the amphetamine compound.

Claims (11)

1 . A method of treating a cognitive impairment in a human with Alzheimer's disease, comprising the step of administering an effective amount of a composition that includes at least about 85 mole percent l-amphetamine relative to the total amphetamine content of the composition to the human.

2 . The method of claim 1 , wherein the compositions administered to the human includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition.

3 . The method of claim 1 , wherein memory is improved in the human following administration of the amphetamine.

4 . The method of claim 3 , wherein the improvement in memory is an improvement in at least one member selected from the group consisting of an improvement in short-term memory, long-term memory, memory consolidation, procedural memory and declarative memory.

5 . The method of claim 1 , wherein attention is improved in the human following administration of the amphetamine.

6 . The method of claim 1 , wherein executive function is improved in the human following administration of the amphetamine.

7 . The method of claim 1 , wherein reaction time is improved in the human following administration of the amphetamine.

8 . The method of claim 1 , wherein learning is improved in the human following administration of the amphetamine.

9 . A method of treating a cognitive impairment in a human with_Alzheimer's disease, comprising the step of administering an effective amount of a composition that includes at least about 85 mole percent l-amphetamine relative to the total amphetamine content of the composition to the human and wherein the l-amphetamine is administered at a dose of at least about a 2 mg and about a 60 mg dose per day.

10 . A method of treating a cognitive impairment in a human with Alzheimer's disease, comprising the step of orally administering an effective amount of a composition that includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition to the human and methamphetamine content of the composition is l-amphetamine and wherein the l-amphetamine is administered at a dose of at least about a 2 mg and about a 60 mg dose per day.

11 . A method of treating a cognitive impairment in a human with Alzheimer's disease, comprising the step of orally administering an effective amount of a composition that includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition to the human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2013
From: EPSTEIN, MEL H.; WIIG, KJESTEN A.; BEAR, MARK F.
To: COGNITION PHARMACEUTICALS, LLC
Reel/Frame 031828/0224 →